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ABSTRACT	  Objective:	  	  	  The	  objective	  of	  this	  selective	  EBM	  review	  is	  to	  determine	  whether	  or	  not	  the	  addition	  of	  a	  topical	  agent	  to	  narrowband	  UVB	  treatment	  is	  more	  effective	  in	  treating	  adults	  with	  psoriasis	  than	  narrowband	  UVB	  treatment	  alone.	  	  Study	  Design:	  	  Review	  of	  three	  English	  language	  primary	  randomized	  trials	  that	  were	  published	  between	  2003	  and	  2012.	  	  	  Data	  Sources:	  	  A	  randomized	  left-­‐right	  comparison,	  placebo	  controlled	  clinical	  trial,	  a	  randomized	  trial,	  and	  a	  randomized	  placebo	  controlled,	  blinded	  clinical	  trial	  each	  comparing	  the	  addition	  of	  a	  topical	  agent	  to	  narrowband	  UVB	  treatment	  to	  narrowband	  UVB	  treatment	  alone	  were	  found	  using	  PubMed	  and	  Cochrane	  databases.	  	  	  Outcomes	  Measured:	  	  The	  outcomes	  were	  measured	  by	  a	  single	  investigator	  in	  each	  trial	  by	  analyzing	  the	  improvement	  of	  the	  lesions	  based	  on	  the	  induration	  size,	  redness,	  and	  scaliness	  using	  Psoriasis	  Area	  and	  Severity	  Index	  (PASI)	  and	  Psoriasis	  Severity	  Index	  (PSI)	  scores.	  	  	  	  Results:	  	  The	  results	  of	  these	  trials	  indicate	  that	  the	  addition	  of	  a	  topical	  agent	  to	  narrowband	  UVB	  can	  be	  effective	  in	  treating	  psoriasis.	  The	  Ehsani	  et	  al	  study	  concluded	  that	  while	  the	  use	  of	  8MOP	  resulted	  in	  a	  greater	  score	  decrease,	  the	  decrease	  between	  groups	  was	  not	  significant.	  	  The	  Woo	  et	  al	  study	  concluded	  that	  while	  the	  difference	  in	  PASI	  scores	  between	  the	  groups	  was	  not	  significant,	  the	  active	  group	  using	  calcipotriol	  for	  psoriasis	  received	  less	  UVB.	  	  The	  Ozkan	  et	  al	  study	  concluded	  that	  the	  group	  treated	  with	  calcipotriol	  had	  statistically	  significant	  improvement	  compared	  to	  UVB	  monotherapy.	  	  	  	  Conclusions:	  	  The	  results	  indicate	  that	  the	  addition	  of	  a	  topical	  agent	  to	  UVB	  therapy	  for	  adults	  with	  psoriasis	  is	  just	  as	  effective	  as	  NBUVB	  alone.	  	  While	  the	  use	  of	  8MOP	  didn’t	  produce	  statistically	  significant	  results,	  the	  trials	  that	  used	  calcipotriol	  had	  favorable	  outcomes.	  	  The	  Woo	  et	  al	  study	  concluded	  that	  calcipotriol	  may	  produce	  UVB	  enhancing	  effects	  resulting	  in	  less	  cumulative	  UVB	  exposure.	  	  The	  Ozkan	  study	  concluded	  that	  the	  addition	  of	  calcipotriol	  to	  UVB	  phototherapy	  is	  more	  effective	  and	  efficient	  in	  treating	  the	  lesions.	  	  Further	  study	  is	  warranted	  to	  evaluate	  the	  use	  of	  calcipotriol	  and	  NBUVB	  phototherapy	  for	  the	  treatment	  of	  psoriasis.	  	  Key	  Words:	  	  psoriasis;	  narrowband	  UVB;	  phototherapy;	  topical	  psoriasis;	  	  ultraviolet	  B;	  plaque	  psoriasis	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INTRODUCTION 
 Psoriasis is a relatively common, chronic inflammatory dermatologic condition 
characterized by well demarcated, erythematous plaques with silver scales that can be 
caused by injury of the skin, infections, heightened stress levels or even medications.1   
The exact etiology of psoriasis is unknown but it is theorized to have a genetic 
component and thought to be due to over-activation of T-cells and inflammatory 
cytokines because of the positive response to treatment regimens.   Although there are 
multiple types of psoriasis, plaque psoriasis makes up about 80% of all cases and is 
commonly characterized by red plaques with scales that typically occur on the patient’s 
scalp, knees, elbows, and back.  Although the disease is often asymptomatic, mild to 
severe itching may occur, as well as burning, skin pain, or Auspitz sign, which is tiny pin 
point bleeding when a scale is removed.2  Despite the lack of symptoms, psoriasis can 
lead to disfiguring disability and decreased quality of life. Therefore, the decision to start 
treatment is often based on the social and psychological impact it has on the patient.    
 Psoriasis is a common dermatologic and the most common autoimmune problem 
in the United States.  It affects over 125 million people worldwide and 7.5 million of 
those cases are in the United States.3   With that many people affected by the disease, it is 
no surprise that around 11.25 billion dollars are spent annually on health care costs 
related to psoriasis.  This estimate also includes the cost of days of work patients had to 
miss due to their disease.  It is also estimated that there are 3 million visits to 
dermatologists each year for psoriasis.2  This topic is important for all practitioners to be 
educated about because it is such a common problem and it can have such a negative 
impact on patients’ lives, not only physically but also financially and emotionally.
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There is currently no cure for psoriasis, so treatment is aimed at the reduction in 
the size and appearance of the lesions based on the extent of the disease.  Even patients 
with mild disease are very self-conscious of these red, scaly lesions.  Patients with mild 
disease are advised to keep their skin moisturized with creams and for flares they can use 
topical corticosteroid creams, such as triamcinolone 0.1%, over the affected area.  These 
steroid creams have side effects and can eventually be less effective, therefore a vitamin 
D analog, such as calcipotriene ointment 0.005% or calcitriol ointment 0.003% is often 
added to the treatment.  For patients that have lesions on their scalp, it is possible to get 
the corticosteroids in solution form or they can also use an over the counter tar shampoo.4    
In patients with more generalized disease, the use of phototherapy, both UVB and UVA, 
has been proven to be effective in controlling the lesions, but comes with risks of its own, 
including melanoma.  There are also various systemic agents that can be used to treat 
severe cases of psoriasis including methotrexate, cyclosporine, and retinoids such as 
acitretin.  Another option for treatment includes TNF inhibitors such as etanercept, 
infliximab, and adalimumab.2,4  
All of the agents mentioned above can be used to control the symptoms of the 
psoriasis, however it is important to consider the possible adverse reactions and side 
effects the medications will have and whether or not the benefits of treatment outweigh 
the risks.  While phototherapy has been proven to be effective in the treatment of 
psoriasis, it is costly, prolonged and is likely to have issues with compliance in addition 
to its physical side effects.  Therefore, this paper investigates the use of an adjunctive 
topical therapy to enhance the efficacy of narrowband UVB treatments.
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OBJECTIVE 
 The	  objective	  of	  this	  selective	  EBM	  review	  is	  to	  determine	  whether	  or	  not	  the	  addition	  of	  a	  topical	  agent	  to	  narrowband	  UVB	  treatment	  is	  more	  effective	  in	  treating	  adults	  with	  psoriasis	  than	  narrowband	  UVB	  treatment	  alone.	  	  	  
METHODS	  
	   In	  order	  to	  be	  considered	  satisfactory,	  the	  population	  studied	  had	  to	  be	  patients	  over	  the	  age	  of	  18	  who	  had	  been	  clinically	  diagnosed	  with	  chronic	  psoriasis.	  The	  study	  had	  to	  be	  a	  randomized	  trial	  that	  used	  narrowband	  UVB	  phototherapy	  monotherapy	  compared	  to	  narrowband	  UVB	  therapy	  with	  the	  addition	  of	  a	  topical	  agent.	  	  The	  control	  group	  in	  each	  study	  was	  a	  group	  who	  only	  received	  narrowband	  UVB	  monotherapy,	  with	  or	  without	  the	  addition	  of	  a	  placebo.	  	  The	  topical	  interventions	  studied	  included	  0.1%	  8-­‐methoxypsoralen	  (8MOP)	  cream5,	  0.1%	  psoralen	  gel6,	  .005%	  calcipotriol	  ointment6,	  and	  50	  μg	  g-­‐1	  calcipotriol	  cream	  7.	  	  The	  outcomes	  were	  based	  on	  the	  overall	  improvement	  of	  the	  psoriasis	  lesions	  based	  on	  redness,	  induration	  size,	  and	  scaliness	  of	  the	  lesions	  all	  of	  which	  affect	  the	  patients’	  quality	  of	  life.	  	  The	  studies	  used	  included	  one	  randomized	  left-­‐right	  comparison,	  placebo	  controlled	  clinical	  trial,	  one	  randomized	  trial,	  and	  one	  randomized	  placebo	  controlled,	  blinded	  clinical	  trial.	  	  	  	   In	  order	  to	  find	  appropriate	  articles,	  the	  keywords	  that	  were	  used	  included:	  	  psoriasis;	  narrowband	  UVB;	  phototherapy;	  topical	  psoriasis;	  ultraviolet	  B;	  plaque	  psoriasis.	  	  Only	  articles	  written	  in	  English	  were	  considered	  and	  they	  had	  to	  be	  published	  in	  peer-­‐reviewed	  journals.	  	  The	  author	  used	  the	  previously	  mentioned	  keywords	  to	  search	  the	  PubMed	  and	  Cochrane	  databases	  that	  addressed	  the	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questions	  and	  had	  patient	  centered	  outcomes	  based	  on	  the	  appearance	  of	  the	  lesions.	  	  In	  order	  to	  be	  considered,	  the	  articles	  had	  to	  be	  randomized	  trials	  that	  used	  narrowband	  UVB	  treatment	  and	  were	  published	  after	  the	  year	  1996	  in	  order	  to	  ensure	  up	  to	  date	  information.	  	  Reasons	  an	  article	  would	  be	  rejected	  included	  consenting	  patients	  under	  the	  age	  of	  18,	  broadband	  UVB	  phototherapy,	  or	  UVA	  phototherapy.	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Table	  1:	  	  Demographics	  and	  Characteristics	  of	  Included	  Studies	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14 Twice daily Calcipotriol	  cream	  50	  μg	  g-­‐1	  plus	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  daily	  topical	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  as	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Wagner:	  Topical	  &	  UVB	  treatment	  of	  Psoriasis	  	  	  	  6	  
	  
OUTCOMES	  MEASURED	  The	  outcomes	  were	  measured	  by	  a	  single	  investigator	  in	  each	  trial	  by	  analyzing	  the	  improvement	  of	  the	  lesions	  based	  on	  the	  induration	  size,	  redness,	  and	  scaliness	  using	  Psoriasis	  Area	  and	  Severity	  Index	  (PASI),	  Psoriasis	  and	  modified	  PASI	  scores,	  known	  as	  Psoriasis	  Severity	  Index	  (PSI)	  scores.	  	  Each	  study	  used	  a	  single	  trained	  investigator	  to	  measure	  the	  lesions.	  	  	  The	  measurements	  for	  all	  three	  studies	  were	  primarily	  made	  using	  the	  Psoriasis	  Area	  and	  Severity	  Index,	  which	  divides	  the	  body	  into	  four	  regions,	  and	  then	  assigns	  a	  score	  to	  each	  region	  based	  on	  the	  area	  and	  severity	  affected.	  	  The	  scores	  range	  from	  0	  =	  no	  disease,	  to	  72	  =	  maximal	  disease.	  8	  
RESULTS	  
	   These	  three	  studies	  compared	  the	  addition	  of	  various	  topical	  agents	  to	  narrowband	  UVB	  phototherapy	  for	  adults	  with	  chronic	  psoriasis	  to	  evaluate	  if	  the	  combination	  therapy	  is	  more	  effective	  than	  UVB	  monotherapy.	  	  The	  first	  study	  was	  a	  randomized	  left-­‐right	  comparison,	  placebo	  controlled	  clinical	  trial	  investigating	  the	  use	  of	  8MOP	  with	  UVB.5	  	  	  The	  second	  was	  a	  randomized	  trial	  investigating	  the	  use	  of	  psoralen	  gel	  with	  UVB	  as	  well	  as	  the	  use	  of	  calcipotriol	  ointment	  with	  UVB.6	  	  	  The	  third	  was	  a	  randomized	  placebo	  controlled,	  blinded	  clinical	  trial	  investigating	  the	  use	  of	  calcipotriol	  cream	  with	  UVB.7	  	   In	  the	  study	  by	  Ehsani	  et	  al,	  patients	  used	  were	  those	  who	  had	  symmetric	  lesions	  on	  their	  shins	  that	  would	  be	  useful	  in	  a	  left-­‐right	  comparison	  study.	  	  The	  active	  arm	  of	  the	  study	  received	  0.1%	  8MOP	  cream	  while	  the	  control	  arm	  received	  a	  cold	  cream	  as	  a	  placebo.	  	  The	  researchers	  observed	  a	  significant	  improvement	  in	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Psoriasis	  Severity	  Index	  score	  from	  baseline	  in	  both	  the	  control	  arm	  and	  the	  active	  arm	  (p-­‐value	  <0.001),	  however	  the	  difference	  between	  the	  two	  treatment	  arms	  was	  not	  significant	  at	  p-­‐value	  0.069	  (Table	  2).	  	  	  It	  was	  noted,	  however	  that	  the	  side	  treated	  with	  8MOP	  did	  have	  a	  greater	  decrease	  in	  mean	  percentage	  PSI	  score	  that	  occurred	  earlier	  than	  the	  control	  side.	  	  No	  patients	  in	  this	  study	  exhibited	  complete	  clearance	  of	  lesions.	  	  The	  investigator	  inspected	  for	  side	  effects	  of	  therapy	  each	  week,	  but	  the	  only	  side	  effect	  noted	  was	  pigmentation	  changes.	  	  Due	  to	  this	  visual	  side	  effect,	  the	  investigator	  could	  no	  longer	  be	  blind	  for	  the	  duration	  of	  the	  study.	  5	  




8MOP + UVB 1 
UVB alone 
vs. 
Psoralen + UVB 2 
Calcipotriol + UVB 
vs. 
UVB alone &  
Psoralen +UVB 2 
UVB alone 
vs. 
Calcipotriol + UVB 3 
P-
value 0.069 > 0.05 < 0.05 0.3 
*Statistical significance was considered to be a p-value <0.05 The	  study	  by	  Ozkan	  et	  al	  had	  patients	  in	  the	  active	  groups	  apply	  their	  respective	  psoralen	  gel	  or	  calcipotriol	  ointment	  twice	  per	  day	  where	  the	  control	  group	  only	  received	  the	  UVB	  therapy.	  	  The	  study	  showed	  that	  all	  three	  groups	  had	  statistically	  significant	  improvement	  with	  p-­‐value	  <	  0.05,	  however	  only	  the	  comparison	  of	  Calcipotriol	  ointment	  +	  UVB	  treatment	  with	  the	  other	  two	  groups	  had	  a	  significant	  difference.	  	  Table	  3	  depicts	  the	  improvement	  in	  Mean	  PASI	  score	  from	  baseline	  compared	  to	  the	  end	  of	  the	  treatment	  at	  10	  weeks.	  	  In	  group	  1,	  40%	  of	  patients	  had	  more	  than	  50%	  clearance	  of	  lesions.	  	  Group	  2	  had	  10%	  of	  patients	  with	  more	  than	  50%	  clearance	  of	  lesions.	  	  Group	  3	  had	  100%	  of	  its	  patients	  with	  more	  than	  50%	  clearance	  of	  lesions.	  	  With	  respect	  to	  the	  Calcipotriol	  ointment	  +	  UVB	  therapy,	  the	  Relative	  Benefit	  Increase	  (RBI)	  was	  calculated	  to	  be	  1.5%	  and	  the
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  Absolute	  Benefit	  Increase	  (ABI)	  was	  calculated	  to	  be	  0.6%.	  	  Numbers	  Needed	  to	  Treat	  (NNT)	  was	  calculated	  to	  be	  2,	  indicating	  that	  for	  every	  two	  patients	  treated	  with	  the	  calcipotriol	  ointment	  +	  UVB	  phototherapy,	  one	  more	  patient	  would	  see	  more	  than	  50%	  clearance	  of	  lesions.	  	  	  
Table	  3:	  	  Clinical	  Improvement	  of	  Mean	  PASI	  Scores	  from	  baseline	  to	  10	  weeks	  
	   Group	  1	  UVB	  monotherapy	   Group	  2	  Psoralen	  +	  UVB	   Group	  3	  Calcipotriol	  +	  UVB	  Mean	  PASI	  score	  	  at	  Baseline	   2.72	  +/-­‐	  1.41	   3.25	  +/-­‐	  0.39	   3.66	  +/-­‐	  0.59	  Mean	  PASI	  score	  	  at	  10	  weeks	   1.80	  +/-­‐	  0.88	   2.28	  +/-­‐	  0.42	   1.20	  +/-­‐	  0.42	  	   The	  third	  study	  by	  Woo	  et	  al	  showed	  a	  significant	  decrease	  in	  PASI	  score	  for	  both	  the	  control	  and	  the	  active	  arm	  (p-­‐value	  <	  0.01).	  	  The	  mean	  PASI	  scores	  reduction	  was	  significantly	  lower	  in	  the	  group	  being	  treated	  with	  calcipotriol	  cream	  when	  measured	  at	  the	  eighth	  session	  (95%	  CI,	  1.0-­‐6.2,	  p-­‐value	  =	  0.008).	  	  The	  mean	  score	  reduction	  was	  not	  significant	  when	  measured	  at	  the	  fourteenth	  session	  (95%	  CI,	  -­‐2.2-­‐5.6,	  p-­‐value	  =	  0.4)	  or	  the	  final	  twentieth	  session	  (95%	  CI,	  -­‐5.9-­‐1.9,	  p-­‐value	  =	  0.3).	  	  	  This	  study	  also	  took	  into	  account	  the	  amount	  of	  UVB	  treatments.	  	  The	  active	  group	  received	  a	  mean	  of	  18.7	  treatments,	  compared	  to	  the	  control	  group’s	  mean	  of	  20.4,	  however	  this	  was	  not	  statistically	  significant.	  	  They	  reported	  that	  although	  the	  groups	  did	  not	  achieve	  significantly	  different	  results	  at	  the	  end,	  “we	  have	  identified	  a	  UVB-­‐sparing	  effect	  and	  hence	  a	  possible	  reduction	  in	  the	  risk	  of	  skin	  carcinogenesis”.7	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DISCUSSION	  
	   	  The	  goal	  of	  these	  studies	  was	  to	  determine	  if	  the	  addition	  of	  a	  topical	  agent	  to	  phototherapy	  for	  psoriasis	  enhanced	  the	  treatment’s	  efficacy.	  	  The	  use	  of	  narrowband	  UVB	  is	  widely	  accepted	  as	  part	  of	  treatment	  of	  psoriasis,	  however	  it	  is	  not	  necessarily	  convenient	  or	  without	  side	  effects	  of	  its	  own.	  	  In	  order	  for	  the	  phototherapy	  to	  be	  effective,	  it	  is	  recommended	  that	  the	  patient	  gets	  three	  treatments	  per	  week,	  which	  usually	  has	  improvement	  of	  the	  lesions	  in	  around	  seven	  weeks,	  however	  they	  might	  need	  to	  continue	  in	  order	  to	  maintain	  the	  clearance.4	  	  	  This	  type	  of	  regimen	  might	  be	  difficult	  to	  adhere	  to	  for	  patients	  and	  therefore	  decreases	  the	  compliance	  and	  efficacy	  of	  the	  treatment.	  	  Some	  patients	  even	  run	  into	  issues	  convincing	  their	  insurance	  companies	  that	  it	  is	  a	  necessary	  part	  of	  therapy.	  	  	  	  The	  study	  by	  Woo	  et	  al.	  demonstrated	  that	  although	  the	  addition	  of	  the	  calcipotriol	  agent	  did	  not	  necessarily	  produce	  statistically	  significant	  outcome	  differences,	  it	  did	  reduce	  the	  number	  of	  UVB	  treatments	  required	  for	  the	  active	  arm	  to	  achieve	  the	  same	  results	  as	  the	  control	  group.7	  	  	  The	  study	  by	  Ozkan	  et	  al	  came	  to	  a	  similar	  conclusion	  as	  they	  observed	  moderate	  improvement	  in	  the	  calcipotriol	  group	  compared	  to	  the	  psoralen	  and	  control	  groups	  who	  all	  had	  mild	  improvement.	  The	  study	  concluded	  that	  the	  combination	  of	  calcipotriol	  ointment	  with	  phototherapy	  and	  if	  used	  instead	  of	  monotherapy,	  that	  the	  total	  number	  of	  treatment	  sessions	  could	  be	  reduced.	  	  This	  is	  an	  important	  consideration	  because	  it	  would	  likely	  reduce	  the	  side	  effects	  of	  the	  phototherapy	  experienced	  by	  some	  patients,	  such	  as	  erythema,	  pruritis,	  and	  burning.6	  	  	  A	  noteworthy	  factor	  about	  this	  study	  is	  that	  the	  calcipotriol	  group	  showed	  the	  most	  significant	  improvements	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despite	  starting	  out	  with	  the	  highest	  PASI	  scores	  as	  a	  result	  of	  the	  randomization	  process.6	  	  	  Two	  of	  the	  three	  studies	  reported	  erythema	  and	  pruritis	  as	  an	  adverse	  effect	  of	  the	  phototherapy.	  	  This	  undesirable	  effect	  could	  potentially	  be	  due	  to	  the	  amount	  of	  UVB	  exposure	  the	  patients	  underwent	  during	  therapy,	  therefore	  it	  is	  important	  to	  determine	  if	  less	  exposure	  would	  produce	  less	  side	  effects.	  	  Another	  very	  important	  adverse	  effect	  that	  needs	  to	  be	  considered	  with	  UVB	  therapy	  is	  the	  possibility	  of	  long	  term	  exposure	  leading	  to	  skin	  cancer.1	  	  	  Contraindications	  for	  the	  use	  of	  phototherapy	  as	  treatment	  for	  psoriasis	  include	  a	  diagnosis	  of	  skin	  cancer,	  pregnancy,	  and	  photosensitizing	  medications	  that	  might	  put	  a	  patient	  at	  increased	  risk	  for	  adverse	  effects.	  	  	  All	  of	  the	  studies	  dealt	  with	  relatively	  small	  sample	  sizes	  of	  10,	  30,	  and	  50.	  	  Of	  the	  50	  patients	  in	  the	  third	  study,	  14	  withdrew	  leaving	  them	  with	  only	  36	  patients	  finishing	  the	  trial.	  	  The	  study	  was	  analyzed	  using	  an	  intention-­‐to-­‐treat,	  but	  the	  study	  would	  still	  be	  more	  reliable	  if	  it	  covered	  a	  larger	  population.7	  	  	  Another	  possible	  limitation	  within	  these	  studies	  was	  the	  side	  effect	  observed	  in	  the	  Ehsani	  et	  al	  study.	  	  The	  investigator	  was	  intended	  to	  be	  blind	  as	  to	  which	  group	  was	  the	  control	  and	  which	  was	  the	  active	  until	  the	  active	  group	  treated	  with	  the	  8MOP	  exhibited	  pigmentation	  changes.5	  	  	  These	  studies	  were	  also	  limited	  by	  the	  lack	  of	  consistency	  with	  the	  treatments	  being	  compared.	  	  They	  each	  compare	  different	  topical	  agents,	  dosages,	  vehicles,	  and	  UVB	  exposures.	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